Mather Group LLC. Sells 65 Shares of ResMed Inc. (NYSE:RMD)

Mather Group LLC. cut its holdings in ResMed Inc. (NYSE:RMD – Get Rating) by 4.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,553 shares of the medical equipment provider’s stock after selling 65 shares during the quarter. Mather Group LLC.’s holdings in ResMed were worth $339,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Edgestream Partners L.P. lifted its stake in ResMed by 17.2% in the second quarter. Edgestream Partners L.P. now owns 6,660 shares of the medical equipment provider’s stock valued at $1,396,000 after buying an additional 977 shares during the period. Clarius Group LLC lifted its stake in ResMed by 10.7% in the second quarter. Clarius Group LLC now owns 1,369 shares of the medical equipment provider’s stock valued at $287,000 after buying an additional 132 shares during the period. Mirabella Financial Services LLP lifted its stake in ResMed by 23.1% in the third quarter. Mirabella Financial Services LLP now owns 61,436 shares of the medical equipment provider’s stock valued at $13,412,000 after buying an additional 11,514 shares during the period. Credit Suisse AG lifted its stake in ResMed by 1.4% in the second quarter. Credit Suisse AG now owns 268,421 shares of the medical equipment provider’s stock valued at $56,267,000 after buying an additional 3,784 shares during the period. Finally, Virtus ETF Advisers LLC acquired a new position in ResMed in the second quarter valued at approximately $660,000. 64.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RMD has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price target on ResMed from $245.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, January 27th. William Blair reaffirmed an “outperform” rating on shares of ResMed in a research report on Tuesday, January 31st. Finally, Citigroup raised ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, January 18th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, ResMed has an average rating of “Moderate Buy” and an average price target of $263.17.

ResMed Trading Up 1.1 %

Shares of ResMed stock opened at $208.55 on Wednesday. The stock has a fifty day simple moving average of $218.28 and a 200 day simple moving average of $219.51. ResMed Inc. has a 12-month low of $189.40 and a 12-month high of $262.38. The company has a market capitalization of $30.64 billion, a P/E ratio of 37.85, a price-to-earnings-growth ratio of 1.94 and a beta of 0.48. The company has a current ratio of 3.17, a quick ratio of 1.82 and a debt-to-equity ratio of 0.48.

ResMed (NYSE:RMD – Get Rating) last announced its quarterly earnings results on Thursday, January 26th. The medical equipment provider reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.04. ResMed had a return on equity of 25.46% and a net margin of 21.51%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $996.22 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. ResMed’s revenue was up 15.5% compared to the same quarter last year. On average, sell-side analysts anticipate that ResMed Inc. will post 6.38 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 16th. Investors of record on Thursday, February 9th will be issued a dividend of $0.44 per share. The ex-dividend date of this dividend is Wednesday, February 8th. This represents a $1.76 annualized dividend and a yield of 0.84%. ResMed’s dividend payout ratio (DPR) is currently 31.94%.

Insider Buying and Selling

In other ResMed news, CFO Brett Sandercock sold 4,000 shares of the company’s stock in a transaction on Monday, February 13th. The stock was sold at an average price of $215.00, for a total value of $860,000.00. Following the completion of the transaction, the chief financial officer now owns 116,880 shares in the company, valued at approximately $25,129,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ResMed news, CEO Michael J. Farrell sold 5,675 shares of the company’s stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $215.63, for a total value of $1,223,700.25. Following the completion of the transaction, the chief executive officer now owns 436,900 shares in the company, valued at approximately $94,208,747. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brett Sandercock sold 4,000 shares of the company’s stock in a transaction on Monday, February 13th. The shares were sold at an average price of $215.00, for a total value of $860,000.00. Following the completion of the transaction, the chief financial officer now owns 116,880 shares of the company’s stock, valued at approximately $25,129,200. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,119 shares of company stock worth $6,338,477. 1.39% of the stock is owned by corporate insiders.

ResMed Profile

(Get Rating)

ResMed, Inc engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments.